Literature DB >> 27465822

Rubinstein-Taybi syndrome type 2: report of nine new cases that extend the phenotypic and genotypic spectrum.

Mark J Hamilton1, Ruth Newbury-Ecob, Muriel Holder-Espinasse, Shu Yau, Suzanne Lillis, Jane A Hurst, Emma Clement, William Reardon, Shelagh Joss, Emma Hobson, Moira Blyth, Maryam Al-Shehhi, Sally A Lynch, Mohnish Suri.   

Abstract

Rubinstein-Taybi syndrome (RTS) is an autosomal dominant neurodevelopmental disorder characterized by growth deficiency, broad thumbs and great toes, intellectual disability and characteristic craniofacial appearance. Mutations in CREBBP account for around 55% of cases, with a further 8% attributed to the paralogous gene EP300. Comparatively few reports exist describing the phenotype of Rubinstein-Taybi because of EP300 mutations. Clinical and genetic data were obtained from nine patients from the UK and Ireland with pathogenic EP300 mutations, identified either by targeted testing or by exome sequencing. All patients had mild or moderate intellectual impairment. Behavioural or social difficulties were noted in eight patients, including three with autistic spectrum disorders. Typical dysmorphic features of Rubinstein-Taybi were only variably present. Additional observations include maternal pre-eclampsia (2/9), syndactyly (3/9), feeding or swallowing issues (3/9), delayed bone age (2/9) and scoliosis (2/9). Six patients had truncating mutations in EP300, with pathogenic missense mutations identified in the remaining three. The findings support previous observations that microcephaly, maternal pre-eclampsia, mild growth restriction and a mild to moderate intellectual disability are key pointers to the diagnosis of EP300-related RTS. Variability in the presence of typical facial features of Rubinstein-Taybi further highlights clinical heterogeneity, particularly among patients identified by exome sequencing. Features that overlap with Floating-Harbor syndrome, including craniofacial dysmorphism and delayed osseous maturation, were observed in three patients. Previous reports have only described mutations predicted to cause haploinsufficiency of EP300, whereas this cohort includes the first described pathogenic missense mutations in EP300.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27465822     DOI: 10.1097/MCD.0000000000000143

Source DB:  PubMed          Journal:  Clin Dysmorphol        ISSN: 0962-8827            Impact factor:   0.816


  7 in total

1.  Exploring by whole exome sequencing patients with initial diagnosis of Rubinstein-Taybi syndrome: the interconnections of epigenetic machinery disorders.

Authors:  Gloria Negri; Pamela Magini; Donatella Milani; Milena Crippa; Elisa Biamino; Maria Piccione; Stefano Sotgiu; Chiara Perrìa; Giuseppina Vitiello; Marina Frontali; Antonella Boni; Elisabetta Di Fede; Maria Chiara Gandini; Elisa Adele Colombo; Michael J Bamshad; Deborah A Nickerson; Joshua D Smith; Italia Loddo; Palma Finelli; Marco Seri; Tommaso Pippucci; Lidia Larizza; Cristina Gervasini
Journal:  Hum Genet       Date:  2019-02-26       Impact factor: 4.132

2.  Rubinstein-Taybi syndrome with scoliosis treated with single-stage posterior spinal fusion: illustrative case.

Authors:  Takeshi Imai; Daisuke Sakai; Jordy Schol; Toshihiro Nagai; Akihiko Hiyama; Hiroyuki Katoh; Masato Sato; Masahiko Watanabe
Journal:  J Neurosurg Case Lessons       Date:  2021-03-15

3.  Hyperinsulinism in an individual with an EP300 variant of Rubinstein-Taybi syndrome.

Authors:  K Taylor Wild; Tomoki T Nomakuchi; Sarah E Sheppard; Karla F Leavens; Diva D De León; Elaine H Zackai
Journal:  Am J Med Genet A       Date:  2021-01-14       Impact factor: 2.802

4.  Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.

Authors:  María López; Alberto García-Oguiza; Judith Armstrong; Inmaculada García-Cobaleda; Sixto García-Miñaur; Fernando Santos-Simarro; Verónica Seidel; Elena Domínguez-Garrido
Journal:  BMC Med Genet       Date:  2018-03-05       Impact factor: 2.103

5.  Genetic analysis of CHARGE syndrome identifies overlapping molecular biology.

Authors:  Amanda Moccia; Anshika Srivastava; Jennifer M Skidmore; John A Bernat; Marsha Wheeler; Jessica X Chong; Deborah Nickerson; Michael Bamshad; Margaret A Hefner; Donna M Martin; Stephanie L Bielas
Journal:  Genet Med       Date:  2018-01-04       Impact factor: 8.822

6.  Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.

Authors:  Mohammad M Al-Qattan; Abdulaziz Jarman; Atif Rafique; Zuhair N Al-Hassnan; Heba M Al-Qattan
Journal:  BMC Med Genet       Date:  2019-01-11       Impact factor: 2.103

7.  Genetic and clinical heterogeneity in Korean patients with Rubinstein-Taybi syndrome.

Authors:  Naye Choi; Hwa Young Kim; Byung Chan Lim; Jong-Hee Chae; Soo Yeon Kim; Jung Min Ko
Journal:  Mol Genet Genomic Med       Date:  2021-08-24       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.